LEXARIA BIOSCIENCE CORP. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
LEXARIA BIOSCIENCE CORP. (LEXX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$4.46 million for the 12-month period ending 2023-08-31, per its 10-K filed 2023-11-20.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2023-11-20
- LEXARIA BIOSCIENCE CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2022-11-30 was -$1.28M.
- LEXARIA BIOSCIENCE CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2021-11-30 was -$1.24M.
- LEXARIA BIOSCIENCE CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$4.46M.
- LEXARIA BIOSCIENCE CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was -$5.10M, a 153.04% decline from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2021 was $9.62M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2023-08-31 | -$4.46M 10-K · filed 2023-11-20 | |||
| 2023-05-31 | -$2.65M 10-Q · filed 2023-07-14 | |||
| 2023-02-28 | -$2.54M 10-Q · filed 2023-04-14 | |||
| 2022-11-30 | -$1.28M 10-Q/A · filed 2023-01-18 | |||
| 2022-08-31 | -$5.10M 10-K · filed 2023-11-20 | |||
| 2022-05-31 | -$3.87M 10-Q · filed 2023-07-14 | |||
| 2022-02-28 | -$2.56M 10-Q · filed 2023-04-14 | |||
| 2021-11-30 | -$1.24M 10-Q/A · filed 2023-01-18 | |||
| 2021-08-31 | $9.62M 10-K · filed 2022-11-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |